🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

18,91 USD

Máx. histórico

48,47

1806 días

Caída desde máximo

-60,99%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+5,94%

Cierre anterior

17,85

Rango de hoy

18,05 – 18,98

Volumen hoy

1.935.563

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,63%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 21 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
17/12/2018 12,44 12,51 11,12 11,82 -5,74% 11,17% 282.700
14/12/2018 12,55 13,04 12,48 12,54 -0,32% 4,46% 235.900
13/12/2018 12,31 12,75 12,07 12,58 +2,69% 5,52% 206.600
12/12/2018 12,32 12,79 12,00 12,25 +0,82% 6,37% 217.400
11/12/2018 12,84 13,13 11,83 12,15 -3,88% 10,12% 252.300
10/12/2018 12,23 13,39 11,99 12,64 +3,95% 11,45% 394.900
07/12/2018 11,96 12,30 11,71 12,16 +2,01% 4,93% 121.500
06/12/2018 12,12 12,39 11,59 11,92 -2,85% 6,60% 177.100
04/12/2018 12,60 13,77 12,21 12,27 -4,22% 12,38% 290.900
03/12/2018 11,10 12,96 11,01 12,81 +12,17% 17,52% 190.800
30/11/2018 11,37 11,71 11,05 11,42 -0,17% 5,80% 228.600
29/11/2018 11,52 11,78 11,34 11,44 -0,69% 3,82% 86.900
28/11/2018 10,95 11,89 10,86 11,52 +5,40% 9,41% 142.600
27/11/2018 11,35 11,54 10,86 10,93 -2,93% 5,99% 72.200
26/11/2018 11,81 11,89 11,00 11,26 -3,18% 7,54% 61.300
23/11/2018 11,56 11,94 11,04 11,63 -0,26% 7,79% 84.600
21/11/2018 11,32 12,00 11,13 11,66 +5,81% 7,69% 112.700
20/11/2018 11,21 11,45 10,75 11,02 -3,67% 6,24% 87.000
19/11/2018 11,54 11,79 11,13 11,44 -1,80% 5,72% 137.000
16/11/2018 11,48 11,77 11,11 11,65 +0,52% 5,79% 148.300
15/11/2018 11,27 12,09 11,16 11,59 +2,20% 8,25% 176.900
14/11/2018 11,15 11,66 10,66 11,34 +1,80% 8,97% 378.500
13/11/2018 12,14 12,14 11,00 11,14 -7,17% 9,39% 952.000
12/11/2018 12,34 12,34 11,58 12,00 -2,12% 6,16% 215.800
09/11/2018 12,08 12,59 11,56 12,26 +3,55% 8,53% 176.000
08/11/2018 11,16 11,94 10,87 11,84 +5,15% 9,59% 88.500
07/11/2018 11,10 11,40 10,27 11,26 +0,99% 10,14% 309.200
06/11/2018 10,99 11,22 10,53 11,15 +1,46% 6,28% 395.200
05/11/2018 10,85 11,22 10,48 10,99 +1,67% 6,82% 178.900
02/11/2018 10,69 11,04 10,53 10,81 +2,17% 4,72% 85.000